Lung cancer patients with EGFR mutation (ie, exon 19 deletions or exon 21 L858R point mutations) achieve a substantially increased benefit from treatment with EGFR tyrosine kinase inhibitor, compared with standard chemotherapy [16]. The gene discussed is EGFR; the disease is lung cancer.